Replimune Group Inc 's ROA from the first quarter of 2026 to the first quarter of 2026 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Replimune Group Inc 's ROA in the first quarter of 2026?
Replimune Group Inc recorded a cumulative net loss of $-297 million during 12 months ending in the first quarter of 2026, resulting in a negative return on assets (ROA) of -77.87%.

However, within the Healthcare sector 776 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the fourth quarter of 2026 from 4172 to 4743.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) I. Quarter	(Mar 31 2026) IV. Quarter	(Dec 31 2025) III. Quarter	(Sep 30 2025) II. Quarter	(Jun 30 2025) I. Quarter
Y / Y Total Assets Change	-46.23 %	-39.71 %	13.04 %	-21.83 %	-12.2 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-297	-314	-315	-310	-280
Return On Assets (TTM)	-77.87 %	-72.06 %	-64.2 %	-65.39 %	-55.85 %
REPL's Total Ranking	# 4743	# 4172	# 4136	# 4123	# 4743
Total Assets (TTM) in million	252	332	551	389	470
Seq. Total Assets Change	-24.05 %	-39.71 %	41.57 %	-17.05 %	-14.84 %
Seq. Net Income Change	-	-	-	-	-

REPL's 5 Years Annual ROA >> Back to REPL Management Effectiveness >> Compare REPL ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 119
Sector	# 777
Overall	# 4819

Return On Assets Statistics
High	Average	Low
-20.07 %	-36.06 %	-77.87 %
(Jun 30 2019)		(Jun 30 2026)

News about Replimune Group Inc Return on Assets ROA

Replimune Group Inc. Strategic Investor Engagement Amidst Financial Challenges in Oncolytic Immunotherapy Developme...

This article reviews the recent announcements by Replimune Group, Inc. a biotechnology company specializing in oncolytic immunotherapies. Specifically, it discusses the company s upcoming participation at two investor conferences and analyses the implications of their financial performance, focusing on the revenue generated from corporate clients. Replimune Group, Inc. is at the forefront of developing innovative therapies aimed at treating various forms of cancer through oncolytic immunotherapy. As a clinical-stage organization, Replimune is actively pursuing advancements in treatment mechanisms that harness the body s immune system to target and destroy tumor cells.

Replimune Group Inc Gains FDA Alignment for RP1 Accelerated Approval Pathway, Inspiring 11.54% Share Price Surge in Q3 2024,

Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024
- Alignment with FDA on accelerated approval pathway for RP1 in anti-PD1 failed melanoma
- Share price increases by 11.54% in Q3 of 2024
- Cumulative net loss of $-220 million with a negative return on assets
- Ranking improves to 3241 in overall ROA ranking
Replimune Group Inc, a prominent player in the field of oncolytic immunotherapies, recently disclosed positive developments regarding their accelerated approval pathway for RP1 in anti-PD1 failed melanoma. The company had a successful Pre-BLA (Biologics License Application) meeting with the Food and Drug Administration (FDA), solidifying their plans to submit the BLA in the second half of 2024. This news contributed to a significant increase in the company s share price, which rose by 11.54% in the third quarter of 2024.
The alignment with FDA on the accelerated approval pathway for RP1 marks a crucial milestone for Replimune Group Inc. Accelerated approval has become an increasingly desirable pathway for pharmaceutical companies, offering faster access to potentially life-saving treatments. By obtaining alignment with the FDA, Replimune now has a clearer timeline and regulatory path for RP1, a potential breakthrough therapy for patients with anti-PD1 failed melanoma.

Replimune Appoints New CEO and Strengthens Executive Team as Shares Surge

Replimune Announces Leadership Transitions and Strengthened Executive Team as Shares Trade Higher
Replimune Group Inc, a renowned biotechnology company specializing in oncolytic immunotherapies, has recently announced significant leadership transitions and the appointment of Sushil Patel as CEO. The company s former CEO, Philip Astley-Sparke, will now assume the role of Executive Chairman. This move aims to enhance Replimune s growth strategy and support its mission to revolutionize cancer treatment.
In addition to the management shakeup, Replimune also revealed its financial performance for the past year. The company recorded a cumulative net loss of $-210 million during the twelve months ending in the third quarter of 2024, resulting in a negative return on assets (ROA) of -35.81%. However, despite the financial challenges, Replimune s return on assets has improved significantly, moving up to 2554 from its previous ranking at 3809 in the second quarter of 2024.
Replimune operates within the highly competitive Healthcare sector, where 286 other companies boast higher return on assets. Nevertheless, the company s recent advancements indicate positive strides towards achieving its financial goals and solidifying its position in the industry.

Financial Statements
Replimune Group Inc 's Assets	$ 252 million	REPL's Balance sheet
Replimune Group Inc 's Income	$ -70 million	Quarterly REPL's Income Statement
REPL's Income by Division		See REPL's Income by Division

Annual Return On Assets	(Mar 31 2026) FY 2026	(Mar 31 2025) FY 2025	(Mar 31 2024) FY 2024	(Mar 31 2023) FY 2023	(Mar 31 2022) FY 2022
Y / Y Total Assets Change	14.22 %	13.04 %	-24.57 %	40.2 %	-15.08 %
Total Assets in million	630	551	488	647	461
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-314	-247	-216	-174	-118
Annual Return On Assets	-49.85 %	-44.85 %	-44.25 %	-26.95 %	-25.59 %

REPL's 5 Years Annual ROA >> Back to REPL Management Effectiveness >> Compare REPL ROA to its Competitors

More Return On Assets Ratios
REPL's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
REPL's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for REPL's Competitors
Subscribers only: Roa for Replimune Group Inc 's Suppliers
Subscribers only: Return On Assets for REPL's Customers

You may also want to know
REPL's Roi	REPL's Inventory Turnover Ratio	REPL's Growth Rates	REPL's Dividend Comparisons
	REPL's Profitability Ratios	REPL's Asset Turnover Ratio	REPL's Dividend Growth
REPL's Roe	REPL's Valuation Ratios	REPL's Financial Strength Ratios	REPL's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-08-15T21:41:14+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.